Overview

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Status:
Unknown status

Trial end date:
2018-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma or gastric cancer. Apatinib is a small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib. SHR-1210 is a humanized anti-PD-1 monoclonal antibody.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Treatments:

Apatinib